Groch will be responsible for all sales and marketing activities of the Company, with the goal of coordinating prelaunch, launch, and sales and marketing activities to gain market share and drive business growth. He will develop, implement and manage the prescription products infrastructure for the overall commercial organization, including reimbursement, market access, payer policies, sales and marketing, inventory and distribution, trade, and customer service.
“Brian brings an extensive commercial background, having served in senior leadership positions for some of the best known and highly regarded companies in our industry,” said Dr. Steiner. “He has deep experience across multiple therapeutic areas, such as oncology, urology, neurology and cardiology, among others, and an outstanding record of success developing and executing global marketing strategies, generating brand awareness and launching new products. In his new role as chief commercial officer, he will oversee all aspects of sales and marketing. The initial focus for his team will be to establish the FC2 prescription business infrastructure to produce new and immediate revenue in the US, to coordinate the prelaunch and launch activities for Tamsulosin DRS (Tamsulosin HCl extended release for oral suspension) for the treatment of benign prostatic hyperplasia and manage the marketing and sales activities for PREBOOST®, our recently launched proprietary over the counter (OTC) product for the management of premature ejaculation. We are pleased to welcome Brian and look forward to having his strategic commercial leadership strengthen our management team.”
Groch has more than 30 years of experience in the pharmaceutical and biotechnology industries specializing in lobbying health policy change, global sales leadership, marketing, trade and distribution, contract negotiations, presentations and client/patient relations. He has commercial expertise in a range of therapeutic areas, which includes Oncology, Urology, Immunology, Neurology, Rare & Ultra-Rare Disease, Cardiology, Osteoporosis and Ophthalmology. Groch most recently served as Chief Commercial Officer of Telesta Therapeutics overseeing the global commercial strategy for the first new biologic for bladder cancer. He began his career at
Groch earned a Master of Science degree in
More information about the
Contact: Kevin Gilbert 312-366-2633
Press Release Kari Sharp